Catalyst Sees FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomy, Healthcare

 Catalyst Pharmaceuticals Inc 

CPRX+17.2%+ Free Alerts

 anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y.

• For FY21 total revenues are estimated to be approximately $141 million, an increase of roughly 18% Y/Y, better than the consensus of $138.3 million.
• Last week, Catalyst announced that the District Court Judge in its case against the FDA had issued an order granting Catalyst Summary Judgment in its action against the FDA.
• As a consequence of that order, the FDA has invalidated Jacobus Pharmaceutical Company Inc's Ruzurgi approval for pediatric patients with Lambert-Eaton myasthenic syndrome. 
• The Company has ended the year with cash and investments of approximately $191 million, with no funded debt.
• Guidance: The Company forecasts FY22 sales of $195 million - $205 million, representing a 38%-45% Y/Y increase, compared to the consensus of $163.53 million.

https://www.benzinga.com/general/biotech/22/02/25449790/catalyst-pharma-expects-fy22-revenue-beat-consensus-on-continued-recovery-in-macroeconomic-health